<DOC>
	<DOCNO>NCT00002355</DOCNO>
	<brief_summary>To determine clinically safe effective dose intravitreally inject ISIS 2922 compare safety efficacy immediate versus delay treatment AIDS patient previously untreated , peripheral cytomegalovirus ( CMV ) retinitis .</brief_summary>
	<brief_title>A Comparison ISIS 2922 Used Immediately Later Patients With Cytomegalovirus ( CMV ) Eyes</brief_title>
	<detailed_description>In Stage 1 ( dose escalation ) , patient receive either 75 150 mcg intravitreal ISIS 2922 . In Stage 2 ( randomization ) , patient enrol either immediate treatment group delay treatment group . Immediate treatment consist intravitreal ISIS 2922 every 7 day 3 injection ( Induction ) every 14 day 18 week ( Maintenance ) . Patients delayed treatment group receive immediate anti-CMV treatment monitor weekly disease progression . If disease progress , patient receives ISIS 2922 identical dosage regimen immediate treatment . Patients may continue ISIS 2922 biweekly extend maintenance schedule dose consider safe CMV retinitis clinically control . Per 2/8/96 amendment , patient Stage 2 150 mcg .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Fomivirsen</mesh_term>
	<criteria>Inclusion Criteria Patients must : AIDS . Clinical diagnosis previously untreated peripheral CMV retinitis one eye . Leading edge CMV retinitis lesion least 750 micron zone one . NOTE : Patients CMV retinitis zone three may eligible lesion reliably photograph follow progression . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition eye treat exclude : External ocular infection . Other herpetic infection retina , toxoplasma retinochoroiditis , disease fundus . Ocular condition obstruct visualization posterior ocular structure . Retinal detachment . Silicone oil eye . Patients follow symptoms condition exclude : Known suspect allergy phosphorothioate oligonucleotides . Syphilis . Pseudoretinitis pigmentosa . Concurrent Medication : Excluded : Current treatment extraocular CMV infection . Ganciclovir . Foscarnet . Mellaril . Stelazine . Thorazine . Clofazimine . Ethambutol/fluconazole combination . Investigational medication CMV retinitis . Concurrent Treatment : Excluded : Investigational procedure CMV retinitis . Patients follow prior condition exclude : History surgery correct retinal detachment eye treat . History syphilis . Prior Medication : Excluded : Prior antiCMV retinitis treatment either eye . AntiCMV therapy extraocular infection within past 2 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1998</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>Cytomegalovirus Retinitis</keyword>
</DOC>